Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/PTSD

Esketamine for PTSD

1 paper and 3 clinical trials exploring esketamine as a treatment for ptsd.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationAround 3.9% of people develop PTSD in their lifetime

PTSD

Post-traumatic stress disorder (PTSD) is where psychedelic medicine has its most famous result and its hardest reality check. MDMA-assisted therapy ran the only completed Phase 3 programme for any psychedelic in PTSD, with striking numbers, yet in August 2024 the US regulator declined to approve it and asked for another trial. This page sets the strongest evidence in the field beside the unresolved doubts about blinding, durability and trial conduct that the regulator flagged.

Full PTSD profile

Academic Research

1 paper
Paywallindividual

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

This retrospective observational cohort study (n=966 esketamine initiators, n=39,219 controls) examines factors influencing esketamine initiation and continuation for treatment-resistant depression (TRD). Initiators resided closer to treatment centres, with initiation rates decreasing significantly with distance. Factors associated with increased initiation included posttraumatic stress disorder, suicidal ideation, and male sex, while Medicaid, substance use disorder, older age, and greater distance were associated with lower initiation rates.

Published
May 6, 2024
Journal
Journal of Clinical Psychiatry
Authors
Joshi, K., Liberman, J. N., Parab, P., Darer, J. D., Harding, L.

Clinical Trials

3 trials
RecruitingPhase II

Ayahuasca, Esketamine and PTSD

This Phase II, randomized, double‑blind, parallel trial (n=10) will evaluate the effects of a single oral dose of ayahuasca versus oral esketamine in adults with posttraumatic stress disorder (PTSD), with the primary outcome measured by the Posttraumatic Stress Disorder Checklist for DSM-5 from enrolment to the end of treatment at 3 weeks. Adults aged 18 to 65 years meeting criteria for PTSD will be randomised to one of two arms—experimental oral ayahuasca or active‑comparator oral esketamine—each administered as a single dose; participants with psychiatric or other medical comorbidities are excluded. The study is sponsored by the University of Sao Paulo, is due to start on 20 December 2025, and has an estimated completion in July 2026.

Started
December 20, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT07317206
CompletedPhase I/II

Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)

This open-label, proof-of-concept trial (n=8) will investigate the feasibility and effects of combining intranasal esketamine (28-84mg) with Prolonged Exposure (PE) therapy for the treatment of post-traumatic stress disorder (PTSD). Participants will receive 10 sessions of PE in a massed format over two weeks, alongside esketamine administered six times (three times per week) approximately one hour after specific PE sessions.

Started
February 20, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06795659
Enrolling by invitationPhase NA

Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions

This observational cohort study (n=200) will assess whether a speech-based machine learning algorithm can predict treatment response to psychiatric interventions, specifically repetitive transcranial magnetic stimulation (TMS) and Spravato (esketamine) nasal spray.

Started
February 1, 2025
Type
observational
Randomized
No
Registry ID
NCT06823024

Explore further

Search all Esketamine papers Search all PTSD trials Full Esketamine profile Full PTSD profile